Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AR 101 (Primary)
Indications Peanut hypersensitivity
Focus Registrational; Therapeutic Use
Acronyms POSEIDON
Sponsors Aimmune Therapeutics; Stallergenes Greer plc

Most Recent Events

20 Nov 2023 Results published in the Stallergenes Greer media release.
20 Nov 2023 According to a Stallergenes Greer media release, full study data were published in the New England Journal of Medicine Evidence.
27 Feb 2023 Results reporting safety outcomes presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight